Rockville, Md. (June 03, 2024) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, announced today the addition of Dr. Edward Coles, Ph.D., to the team as Vice President of Program Management and Product Development Lead.
Cellphire is thrilled to announce the appointment of Ed to our Program Management and Executive Leadership teams. Ed's extensive background includes drug development leadership and management, spanning over 15 years across large (MedImmune/AstraZeneca), medium (Regenxbio), and small (Georgiamune) biotech companies. With additional success as a research scientist, his collective skills and experiences will be instrumental in advancing our vision.
“Ed is a great addition to the Cellphire team,” said Mike Gaffney, Chief Executive Officer. “He brings a wealth of experience, technical knowledge, program leadership, and team-building skills to Cellphire, which will be crucial as we continue to mature our team and advance our programs. With the strong technologies we have in development, experienced program leadership is instrumental to achieving approval and getting our products to patients in need.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic, platelet derived, cellular therapeutics. Cellphire is applying its proprietary technologies to develop lifesaving products. With two hemostatic products in Phase 2 clinical development, Cellphire’ s technologies address significant unmet needs for hemostatic therapeutics. Across the range of geographies, clinical settings and indications. These include rural and 3rd world use, Orphan populations, perioperative use for surgery and trauma, and brain hemorrhage. For more information, visit Cellphire Therapeutics at www.Cellphire.com.
Contact Information:
Robert Woods
VP, Business Operations
RWoods@Cellphire.com